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ABSTRACT
The carbamolyating activity of Clore~ine, a novel anticancer prodrug, modifies protein
function and acts synergistically with the choroethyalting species, which a1kylales DNA. The
reactive subspecies responsible for carbamolylating activity is methyl isocyanate, which reacts
with sulfhydryl groups and amines.

DNA repair enzymes have been identified as potential

targets for the modification by methyl isocyanate; in particular, base excision repair enzymes.
Enzymes in DNA base excision repair include DNA polymerase beta (pol fj) and
apurinic/apyrimidic endonucease-l (APElRef-l). APElRef-l hydrolyzes the 5 -phosphodiester
J

DNA backbone from an abasic DNA template, where the base was excised by a DNA
glycosylase. The entire nucleotide is then re-inserted by the nucleotidyl transferase activity of
Pol fj, which also cleaves the 5' -deoxyribose phosphate via lyase activity. Previous research in
oUI laboratory investigated the inhibition of Pol fj's AP lyase and nucleoside transferase activity.
Cloretazine's carbamoylating activity inhibits the nucleotidyl transferase activity of Pol-fj, but
not its lyase activity. An efficient enzymatic assay was developed and used to determine lhe
anticancer drug's effect on APEfRef-l's hydrolytic activity. We found that the endonucleolytic
activity of APE-l is not significantly inhibited by Cloretazine.

INTRODUCTION
Cancer Chemotherapy
The initial efforts to combat cancer date back to the early 19405 with the use of nitrogen
mustard, previously used for chemical warfare, as a chemotherapeutic agent. The treatment was
designed as a result of mutagenic characteristics found in many deceased soldiers during World
War I from exposure to mustard gas (iJ2). Side effects of the gas included underdeveloped and
decreased cell counts in vital organs and decreased bone marrow density. The agent was used to
treat non-Hodgkin's lymphoma, where an active ethyleneimmoruum ring, an alkylating
intermediate, forms and reacts with the electron donating sites on DNA bases to create a covalent
bond (1). The alkylating damage leads to DNA crosslinks and apoptosis. In the 19605 clinical
assays were developed to better understand the cytotoxic effects of cancer treatments. Some
methods use high cytoxic treatments to inhibit cell division, while other agents can physically
damage DNA via alkylation. Because of genetic difference between oncogenes and normal
genomes

in

combination

with

advanced

molecular

biology

techniques,

additional

chemotherapeutic compounds focus on metabolically targeted therapies.
Advancements in biochemistry and molecular and cell biology prompted the
development of targeted therapies that have revolutionized anticancer treatments (i,3). Targeted
therapies focus on cancer from a genetic and mechanistic level. These therapies analyze the
human genome and the recognition of genomic sequences that encode specific cancer types.
These treatments are designed to activate or deregulate tumor cellular processing components
and pathways that include signaling proteins, growth factors and kinase cascades (4). These
anticancer agents possess increased clinical antitumor efficacy, lower toxicities, and lower rates
of drug resistance because of tumor instability (2). One field of research involves the epidermal
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growth factor receptor (EGFR) fam.i!ly.

Studies have shown overexpression of HER-2/neu

proteins in approximately 25% of human breast cancer patients (5).

HER-2/neu encodes a

membrane transport protein that is homologous to EGFR (6). Herceptin (Trastuzumab) was
developed to deregulate tumor cells that had uncontrolled

HER~2/neu

production. The drug

inhibits the formation of a HER-2/neu ligand required for apoptosis (2,5).

Recent studies

documented that Herceptin could also affect vascular endothelial growth factor and angiopoietin
I regulation, and inhibit DNA repair mechanisms (6.7). A combination treatment of Herceptin
and Taxol (paclitaxel), another cancer treatment, showed a 60-70% success rate of anticancer
breast cancer patient treaunents (4).

Pathway-specific chemotherapy suggests high clinical

potential because the therapy targets the signaling pathways critical to tumor growth coupled
with decreased toxic side effects from the treatment. These targeted therapeutic agents will be
based on a mechanistic and a genetic understanding of cancer.
Targeted therapies are being used against a disease that is characterized by undivided cell
division caused by genomic mutations. Molecular targets cannot take into accoWlt all sequence
variability and the variability between patients in different populations (4). Patients must match
the targeted genomic sequences, test positive or negative for specific receptors, and meet various
other clinical parameters for which the study focused on developing a treatment. Additional
complications for targeted therapies include mutations in promoter sequences or within an
oncogene's coding region (2,4). The future advancement of molecular biology techniques will
enhance the potential efficacy of targeted treatments.

The treatments can also be used
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combination with cytoxic chemotherapeutic agents, which increase tumor cell toxicity.
Modem chemotherapeutic agents target specific mechanisms to prevent tumor cell
growth, repair or replication to increase cyotoxicity. For example, antifolatcs block the function
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of enzymes requITing a folate substrate. Sllnilar to nitrogen mustards, antifolates reswt in bone
marrow toxicity; however, the cytotoxic effects of antifolates arc reversible due to brief
remissions and the agents mamtaining their potent anticancer properties (1). Another class of
chemotherapeutic agents is the alkoHds, a natural product with nitrogen containing rings (8).

Vinca alkaloids inhibit mitosis by preventing the formation of microtubules (J,8).

Other

alkaloids include taxanes, such as Taxol, which promote microtubule assembly and are used as
an ovarian cancer treatment (2,8). Furthermore, a campothecin analogue, irinotecan, inhibits
topoisomerase I enzymes that nick and unwind the supercoiled DNA downstream of the
replication fork during DNA replication (1).

Finally, DNA purine analogs, such as 6

mercaptopurine, are used to inhibit the DNA synthesis pathway (J,9).

These analogs are

classified as anti-metabolites that increase cytotoxicity as their anticancer properties.
DNA alkylating agents are also common in cytotoxic anticancer treatments that
physically damage DNA. Preclinical chemotherapy studies continue to include agents designed
to effectively alkylate DNA (10). Alkylating agents act as electrophiles on a nucleophilic site on
7

a DNA base. "Soft electrophiles" prefer to react with soft nucleophiles, like the N and N 3
positions of guanine in DNA. Soft electrophiles that attack the N 7 position of a guanine residue
result in a slow depurination and the hydrolysis of the DNA backbone to create a break in the
DNA strand (ll). Hard electrophiles, however, react more efficiently with hard nuc1eophiles,
like the 0 6 position of guanine or the oxygen-phosphodiester bond in the DNA backbone (12).
Alkylating agents can produce a mixture of alkylated products.

For example, N-methyl-N

nitrosourea alkylatcs 68% at the N position and 7.5% at the 0 6 position (12). Clinically useful
7

alkylating anticancer agents in the chorethylnitrosourea (CENU) class promote DNA crosslinks
in lymphomas and solid brain tumors (13,14). Interstrand crosslinks inhibit DNA replication and

4

transcription J often resulting in a programmed cdl death. The ability of CENU to crosslink
DNA is the primariJy recognized mechanism for the drugJs anticancer properties.

1,3~bis(2

chloroethyl)-l-nitrosourea (BCNU), a common CENU drug, alkylates !DNA in this manner;
however, the mutagenic and carcinogenic side effects limit the agent"s utility (14). BCNU is
commonly used to treat solid brain rumors and breast cancer, and its most common side effect is
a sharp decrease in bone marrow density (15).

BCNU generates toxic reactive species that

i.nclude chloroethylating, hydroethylating, vinylating, and aminoethylating species (14, J6).
These electrophilic species diminish the effectiveness of BCNU's carbamoylating activity and
decrease BCNU's therapeutic index because of the added toxic side effects from these species.
The chloroethylating species is responsible for the DNA cross1inks, where an ethyl group is
added to the 0 6 position of a guanine residue (J 5). The chloroethyl group is rearranged to
eventually create a crosslink. between the Nt position of the guanine residue and the N) position
of the cytosine on the opposite strand (15). HoweverJ the aminoethylating species does not have
a known clinical effect, and hydroyethylating species are carcinogenic. The carbamolyating
species, cWoroethyl-isocyanate, reacts with sulfonyl groups in proteins, and additional effects of
other carbamolyating species are under further investigation (14). Researchers continuously seek
new drugs that lack the toxic side effects yet retain the efficacy of CENUs.

Clorelazine and other suljonylhydrazines
The synthesis of sulfonylhyrazines, a cancer chemotherapeutic agent, possesses similar
anticancer properties to CENUs.

The novel anticancer agent 1,2-bis(methylsulfonyl)-1-2

(methylamino)-carbonyl-hydrazine (Cloretazine) exhibits broad-spectrum anticancer activity
comparable to BCNU (12,13, J4).

Cloretazine is currently in clinical trials for acute myeloid

5

leukemia and has been shown to inhibit enzymes containing thiols, such as glutathione reductase
(18).

The prodrug decomposes (actlvates) into two electrophilic species in the cell, a

chloroethyJating species and a methyl isocyanate compound, which is a carbamoylating species
(Figure I).

/
O=C=N-C1-l 3
metbylisocyanBle

CarbamoylaliQIJ, or ..sH and -NH 2

groups of pro!Cins

l

chlorelhylalion of Q6-guaninc

in DNA

G-C illlerstrarld DNA cross-links

Figure 1. The decomposition of Cloretazme into two active electrophiles, chloroethylating and cabamoylating
electrophiles, and their respective biological targets (J 2).

The two electrophiles act similarly to the reactive species from BCNU, but they are not
structuralJy identical. The aJkyJating compound, 90CE, promotes interstrand guanine-cytosine
crosslinks by cWorethyJating DNA at the 06-guanine position (16,17). The methyl isocyanate,
the carbamolyating species, enhances the cytotoxic effects of the chlorethyJating activity (J 6,18).
This synergism is fundamental to the success of Cloretazine as an anticancer agent.
Cloretazine's synergism contributes to the successful anticancer activity found in vivo.
Finch et 01. reported Cloretazine's anticancer activity against the following murine tumors: P388

6

and LI210 leukemias, Bl6 melanoma, MI09 ltmg carcmomas and M5076 reticuJum cell
sarcoma (l4). They also found prominent anticancer activity in human LX-I lung carcinoma
xenographs.

The L121 0 leukemia mice were treated with a single intraperitoneal dose of

Cloretazine, 10, 20, 40, 60 or 80 mglkg. Comparing the long term survivors of the studies of
Cloretazine and BCNU, Cloretazine illustrated better anticancer efficacy and safety margins. In
vivo resuJts did not show solubility complications or inability of the drug to cross the blood-brain

barrier (14).
In vitro studies have further investigated the anticancer properties of Ctoretazine. Rice et

al. (18) examined inhibition of cellular glutathione reductase (GR). GR activity from purified
enzyme and from cell lysate from LI210 murine leukemia cell lines were treated with 200 !J.M
Cloretazine (half life approximately 1.0 hr, pH 7.4, and 37°C), 90CE (half life approximately 30
s, pH 7.4, and 37°C), and 101MDCE (half life approximately 1.7 min, pH 7.4, and 3rC), and

BCNU (Figure 2). Although isocyanates are toxic species at high concentrations, high doses of
Cloretazine do not decompose to toxic concentration levels of methyl isocyanate. The isocyanate
species plays an important role in the synergism between the carbamylating and choroethylating
species in the clonogenic assays with Chinese hamster ovary cells.

GR inhibition from

CJoretazine, 1OIMDCE, 90CE and BCNU was reported with ICso values of 54.6 ± 4.3 f.lM, 32.7
± 7.7 !J.M, > 1 mM, and 55.5 ± 2.2

1-lM.

respectively (14). Rice el al. hypothesized that an

isocyanate metabolite, rather than the isocyanate itself, transfers the carbamoyl group to a
nucleophile in the enzyme (18).
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o

a~N,.JlN~o
I

Cloreta.zi.ne

H

O~N
BCNU

90CE

Figure 2. Chemical StrucnlreS of anticancer agents used to determined their effects on Human ApurinicJApyridimic
Endonuclease-l Activity.

The guanine-cytosine DNA crosslinks play an important role in Cloretazine's
chemotherapeutic potential. The direct repair DNA mechanism has been previously investigated
because of90CE's cWoroethylating selectivity (18). To repair 06-alkylguanine lesions in double
stranded DNA, 06-alkylguanine transferase (AGT) transfers the alkyl group to an AGT protein's
cystine residue within its active site and deactivates the protein (12,20).

Direct repair of

damaged nucleotides occurs without breaking double stranded DNA. Quantitatively different
AGT expression between some cancerous cell lines and normal cells has increased its potential
role in anticancer treatments. Damia and D'Incalci investigated a link between AGT levels and
tumor cell sensitivity and alkylating agents (20). AGT's interaction with Cloreatzine and its
activated electrophiles have been previously investigated (16).

90CE and methylisocyanates

inactivated the cloned AGT with ICso values of 100 f.l.M and 13 J.lM, respectively. The synergism
between the methytisocyanate and the chlorethylating speices was further recognized as
potentially relevant to Cloretazine's clinical anticancer properties.

Investigating other repair

mechanisms and their respective enzymes would enhance the anticancer properties and the
synergism of Cloreatzine.

DNA Repair Pathway - Base Excision Repair
Due to various chemical and physical DNA damaging agents, approximately 10,000
abasic sites are generated within a genome per day (21). A decrease in genomic integrity can

8

lead to complications of a cellular and developmental level such as apoptosis and cancer,
respectively, if the damage is not properly repaired (22).

Several DNA-repair pathways are

employed within a cell to properly correct a damaged nudeotide base or bases, such as direct
repair of DNA via AGT, the direct reversal of DNA damage. To further maintain genomic
stability, the base excision repair (BER, Figure 3) pathway mends base lesions produced by
oxidative and alkylating damage (21,23,24). BER corrects damaged bases in two pathways,
either short or long patch repair. Long patch BER enzyme activity is similar to DNA replication,
and replaces the damaged nucleotide and a few additional nucleotides around it, typically
between 2-14 nucleotides total (22). Short patch BER, the focus of this study, only replaces a
single nucleotide. Unlike direct repair, this major repair pathway involves several enzymes to
remove the damaged base, perfonn strand incision, and fill the gap, including a DNA
glycosylase, apurinic/apyrimidic endonuclease-l (APElRef-I), and DNA polymerase

~

(Pol

~),

respectively. Long patch BER recruits additional enzymes to mend the larger DNA excision by
DNA synthesis and ligation process that includes DNA polymerase [, and

£,

flap-structure

specific endonuclease-l (FENt), an endonuclease, and Poly ADP-ribose polymerase (pARP)
(22).

.... , •• •1' '1'1.1' .
.... 11111. 1-1 1111 .
1

I'}, I

''''1 I.
1,1;1111 ..
.... lill.II,'-'III ..

~-

~
\

-/

Figure 3. Base Excision Repair Pathway. J\ general mode~ of BER i~lustratcs the single nucleotide replacement
caused by a lesion formed on a nucleotide in double stranded DNA, where the [lesion is represented by R (e.g., 0 6 _
alkylg.oanine).
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A DNA glycosylase cleaves the N-glycosidic bond of the damaged base and leaves a
deoxyribose while the DNA backbone is left intact (21). APEfRef-l then hydrolyzes the sugarphosphate backbone at the 5' side of the abasic site. The cleavage results in 5' -deoxyribose
phosphate and a 3'-hydroxyl group.

Pol

f3

inserts a correct nucleotide base pair, and the

deoxyribose phosphate then undergoes Pol trs lyase activity, a f3-elimination reaction, to form a
4-hydroxy-2-pentenal-5-phosphate (Figure 4) (25). The f3-elimination reaction does not require a
cofactor present; however, the deoxyribose phosphate is processed via hydrolytic cleavage when
a Mg 2 + cofactor is present (14,16). Pol f3 then inserts a correct nucleotide into the abasic site, and
DNA ligase seals the nicked DNA (21,26). In the presence and absence of a cofactor, the two

major enzymes in BER cleave DNA in two different mechanisms.

PoIf3

+

0
I
0=P-Q..-vo3'
I

0

A.

/

~-eliminaLIon

(_ M g2.)

oII

JJ
~

H2 OH!J

"()-P-O-c
I
0
4-hydroxy-2-pcntcnal
5-phosphalc

c.

+

0

0
I

+

Q=P-(}N-3'
I

0

l
0= p-O"'"3'

I
0

D.

Figure 4. AP site mechanisms. The two major enzymes invol\'ed in base excision repair, DNA Pol
1, cleave the AP site of DNA in two different mechanism (26).

~

and APEfRef

10

Poll-~

deaves the DNA after the ribose via

~-elimination

that leaves

eli

5'-phospmate and a

3'-a,~

unsaturated aldebyde tennioiUs (Figure 4A). Alternatively, APEJRef-1 d'eaves the abasic site at the
5' terminus and produces a 5' 2-deoxyribose-5-phosphate (Figure 48).
phosphate is then cleaved into one of two products.

The deoxyribose

In the absence of Mg 2 +, a ~-elimination

reaction occurs and the reaction produces a 4-hydroxy-2-penteoal-S-phosphate (Figure 4C).
Conversely, in the presence of Mg'-+, 2-deoxyribose-5-phosphate forms via hydrolysis (Figure 4D)
(25).

ApurinidApyrimidic Endonuclease- J
This study investigates the effects of Cloretazine on purified human APElRef-l activity.
APElRef-l is a small, bifunctional enzyme, approximately 37 kDa in size, which possesses
excision and reduction-oxidation (redox) activity.

The redox and DNA repair activities are

located in two different domains, the amino-terminus and the carboxyl-terminus, respectively
(27). APElRef-l's excision properties, an alternative pathway to repair 06-alkylguanine lesions,
are responsible for repairing alkylated DNA. HeLa cells studies have shown that high APElRef
1 expression levels decrease the cell's sensitivity to oxidative stress agents (28). Consequently,
increasing the cell's sensitivity to oxidative or aLkylating agents could relate to the cellular levels
of APE/Ref-I and other DNA repair enzymes.
A common side effect of alkylating cancer agents is the myelosuppression, or decrease in
bone density. One method to increase their potency is to increase the myeloid growth factors
and stem cells to help supponthe integrity of the ceB. Recent studies have developed.a chimeric
DNA repair protem to increase the levels of DNA repair enzymes within cells exposed to
alkylating agents (15). Hansen et al. proposed a form of"proteciive" gene therapy by linking the
BER and direct repair pathway by synthesizing a

ch~meric

pr-otein, with both APElRef-1 and

I 11

AGT activity that would repair a broader range of damaged DNA (15).

The study showed that

the AGT-APE protein was functional in in vitro assays. HeLa cells, ovarian cancer cell lines,
were alkylated by both BCNU and methyl methanesu.lfonate (MMS) for 7-10 days. The cells
infected with the chimeric protein demonstrated a 2-fold survival rate when treated with 75 !JM
BCNU and a 4-8 fold survival rate increase with. a 150' ~M BCNU treatment. The 1.0 mM and
2.0 mM MMS-treated HeLa cells illustrated a 10-fold increase in survival rate. Cells that were
exposed to 0.5 roM MMS and 75 !JM BCNU showed an approximate lO-fold increase in survival
rate (15). Hansen el al. demonstrate the possibility to save alkylated DNA in vivo by introducing
increased levels of AGT and APElRef-l activity (15).
APElRef-l is a substrate for serine/theronrne casein kinase I and II and protein kinase C.
The repair activity of APEIRef-l is lost by if the enzyme is phosphorylated by protein kinase C.
However, the inactivity can be reversed to reactivate the protein via a phosphatase treatment
(27). The effects of phosphorylation on the enzyme tie into the redox activity, where APElRef-l
has been shown to stimulate various transcription factors, FOS, JUN and p53 (27). A tumor
suppressor protein., p53, controls the cell cycle, cell survival, and DNA repair pathways (29).
The protein is activated and inactivated by phosphorylation in the correct cellular environment
(27,29). Recent studies have shown that APElRef-l also can influence the oxidation ofp53 to an
activated p53 by the redox activity of APElRef-1 (27). Research on p53 and APElRef-1 has also
revealed that p53 binds to another redox active protein, thioredoxin reductase (TrXR) (29).
TrXR is a small enzyme that reduces. thiroredoxin to TrXR using NAIDPH (28). Seem ani and
Hainant studied the three enzymes together by measuring the expression of APElRef-l, p5J and
TrXR by RNA interference in cells that express wi.ld-type p53. The study showed that inhibitmg
TrXR increased the oxidized form of TrXR and increased p53 DNA binding, whereas the
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inhibition of APEIRef-1 decreases p53 DNA binding (29). When both TrXR and! APElRef~l
were inhibited, p53 binding activity levels remained unaffected (29).

Consequently, ,they

proposed a model in which APElRef-1 and TrXR are a link between BER and p53. APEIRef-1
will repair abasic DNA through its endonuclease activity when it is reduced, and when APEIRef
1 is in its oxidized form, the enzyme activates p53 to stimulate apoptosis. In the model TrXR
oxidizes and reduces APEIRef-I (29). This model links abasic DNA damage to universal DNA
damage which are repaired on a single nucleotide level and as a whole by complete and
programmed cell death, respectively. Further investigation of APEIRef-1 and TrXR will allow a
better understanding of the in vivo repair caused by DNA damage.
Previous work in the Rice lab investigated the inhibition of Pol
Frederick, M. Davis, unpublished work). Pol

~

~

by Cloretazine (A.

studies explored the effects of Cloretazine on the

enzyme's AP lyase and nucleotide transferase activity.

Frederick discovered that the

carbamolyating activity was responsible for inhibiting Pol j3 nucleotide transferase activity, but
not the AP lyase activity. In this work I developed an APEIRef-1 specific assay to measure the
hydrolysis activity levels of APEfRef-1 on 32P-Iabeled oligonucleotides. The method takes into
account the requirement of a

Mi+ cofactor that has been shown to spontaneously cleave DNA,

and minimizes the effects of the cofactor. I also studied the inhibition of Cloretazine at varying
concentrations, (5.0

~M

to 1.0 roM) on the excision repair enzyme.

APElRef-l is an ideal

enzyme for further investigation. The enzyme initiates high efficiency abasite site repair and
plays a crucial role in BER.
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MATERlALS AND METHODS
Materials
Oligonucleotide strands 1 and 2, TACCGCGGCCGGCCAUCAAGCTTAITGGGTAC
and AATGTAceeAATAACGTIGATCGGCCGGCCGCGGTA, respectively, were obtained
from Operon (Huntsville, AL). [a_32p] ciA TP (AA0004, 3000Ci/mmol) was purchased from
Amersham Biosciences (piscataway, NJ). Cloretazine, 10IMDCE, and 90CE were synthesized,
purified, and characterized at Yale University (New Haven, Cn as described elsewhere (11,30).

BCNU was purchased from Sigma (St. Louis, MO). Drugs were dissolved in dry DMSO to
concentrations of 200 mM. Stock solutions were stored desiccated at -20·C for 2 months; all
dilutions were also prepared in dry DMSO.

Purified human apurinic endonuc1ease-l was

purchased from Trevigen, Inc. (Helgerman., en. KIenow exo-l fragments and uracil DNA
glycosylase were purchased from New England Biolabs (Ipswich, MA). All other solvents and
biochemicals were obtained from Fisher Scientific (Pittsburg, PA) unless otherwise noted.

3' DNA end labeling and purification
15 ~M strand 1, 15 IlM strand 2, and 50 nM NaCI were added in a microcentrifuge tube
and the volume was adjusted with distilled water to a total volume of 10 ilL. The oligonucleotide
mixture was incubated at 90°C for approximately 3 min to ensure complete denaturation, and
slowly cooled for 40 min to less than 50°C. The oligonucleotide mixture was then labeled on the

3' end of the strand by using 80 !lCi [a.- 32P]-dATP, 1.0 unit Klenow (exo-l), lax New England
Biolabs Buffer #2, 2.1 roM MgCh, and volume adjusted with distilled water to a total reaction
volume of35 ilL per reaction. The mixture was incubated at 3rC for 30 min. 32P-Iabe1ed DNA
was purified via a QIA Quick Nucleotide Removal kit (Qiagen, Inc., Valencia, CA) according to
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manufacturer's instructions, and eluted in 10mM TrisCI (pH 7.4) and stored at -20°C for up to I
month.

DNA Substrate Preparation
Standard assay conditions included 70 mM HEPES-KOH buffer (pH 7.4), 0.5 rnM
EDTA, 5% glycerol, 1.0 roM tris (2-carboxyethyl)-phosprune hydrochloride (TCEP), 32P-Iabeled
oligonucleotide (24 ""L added volume, 4.77 x 10.8 M fmal concentration) and 20 units of uracil
DNA glycosylase (2.2 ""L added volume) in a total volume of 216 ""L per reaction. This reaction
was incubated at 3rC for 30 min. DNA substrate was stored on ice.

APE Assay

Cloretazine, 10IMDCE, 90CE, BCNU, or DMSO control was preincubated with 2.5

units/j..lL of human APE in lOa mM HEPES-KOH (pH 7.4) buffer for 3.0 hr at room
temperature. 8 mM MgCb and 1.0 unit preincubated APE mixture per reaction were added to
16.0 ilL DNA substrate aliquots and incubated at 3rC for 20 min.

The APE reaction was

quenched with 2.0 M NaBr4.. Equal volume fonnamide (with bromophenol blue and xylene
cyanol dye) was added to the reaction mixture and heated for 2-4 min at 90'C and the reaction

mixrure was cooled on ice. 15% polyacrylamide gels of 0.75 mm thickness were prepared fresh
daily via 40% acrylamide solution (19: 1, acrylamide: bis-acrylamide, electrophoresis grade), 5x
Tris-Borate-EDTA (TBE), and 12% w/v urea while TEMED (15 ilL added volume) and 10%
APS (200 j..lL added volume) were added to polymerize the acrylamide, 25 mL total volume. 11

Il-L aliquots of sample were loaded on the 15% denaturing acrylamide gel and electrophoresed in
a Ix TBE buffer for 30 min at 475 V (45-50'C optimal gel temperature) in a Hoefer SE600
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chroma standard vertical electrophoresis unit powered by a Fisher Scientific FB 1000 power
supply with a Ix TBE buffer. The gel was soaked in a 10% methanol, 10% glacial acetic acid
fIxative on an orbital shaker. Gels were dried for 30 min under vacuum, I hr under 80° Cheat
and vacuum, and then for 30 min under vacuum alone.

The dried gels were placed in a

phosphorimager cassette overnight at room temperature and analyzed quantitatively by
phosphorimaging.

Gels were visualized with the Amersham Biosciences Storm840

Phosphorimager with ImageQuant 5.2 software to quantify the data. Data were normalized to
the positive and negative controls and expressed as percent activity.

APE activity was

determined by calculating the ratio of intact oligionucleotide to hydrolyzed. oligonucleotide
products.
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RESULTS

Ml+ facilitates the spontaneous cleavage ofabasic DNA
Spontaneous DNA cleavage by MgH was investigated by incorporating MgCh at various
points in the uracil DNA glycosylase (UDG) reaction.

Mi+ cleavage of DNA was measured as

a ratio of cleaved DNA product ratio with respect to intact DNA with
addition of 8 roM MgCh before and after the

NaB~

Mi+ (Figure

5). The

quench shows an increase in spontaneous

cleavage. The cleaved DNA band, a smaller size than the intact DNA, appears in lanes 3-4 only
when MgCh was present in the UDG assay. Additional studies were preformed to examine the
effects of no MgCh in the UDG reaction. Because Mg 2+ is not a cofactor for UDG, the studies
did not illustrate new information (results not shown). The banding pattern result of the UDG
reaction alone is equivalent to 32P-labeled DNA oligonucelotide banding pattern.

The

glycosylase reaction removes the uracil and the enzyme does not affect the phosphodiester
backbone, thus the reaction cannot be visualized on a 15% denaturing polyacrylamide gel.
2

3

4

5

Intact DNA
substrate

MgCl 2 cleaved
DNA

Figure 5. Uracil Deg Iycos lyase Assay in, the presence of 8 mM MgCh. Lanes 1 and 5 represent the intact 32 p 
labeled DNA (used as a radioactive size ladder). 8 mM MgCh was added to the glycoslyase reaction buffer and the
protocol followed the UDG assay as described in the experimental methods section (Lane 2). 8 mM MgCh was
added before (Lane 3) and after (Lane 4) the UGD reaction was Slopped with NaBH4 • The positions of the intact
DNA and the cleaved DNA are indicated.

Decreasing the APE/Ref] incubation time from manufacture's specifications allows clear
quantification ofenzyme activity,
The UDG reaction with MgCh was expanded to examine the products of APElRef-l and
Pol

~

cleavage (data not shown). Pol j} acts as the positive DNA cleavage control. To optimize

the APElRef-l specific assay, the enzyme concentrations were varied from 1.0 unit/ilL, 0.18
unit/I-lL, and 0.09 unit/ilL.

The results showed that the 1.0 unit/ilL and the 0.09 unit/I-lL

APElRef-l total assay reactions possessed too much enzyme or too little enzyme concentrations,
respectively, for efficient hydrolysis of the labeled oligonucleotide (results not shown). Trevigen
defmes the unit definition for APElRef-l as one unit of enzyme hydrolyzes I pmol of abasic
DNA oligonucleotid eIhr.

The optimal APElRef-l assay was constructed with 0.18 unit/ilL

APElRef-l, 8 mM MgCb, and incubated for 40 min (Figure 6). The hydrolysis of DNA over
time resulted in a hyperbolic curve that reaches a maximum of 80% of total hydrolysis of the
abasic DNA substrate at 40 min.
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Figure 6. Hydrolysis ofabasic DNA. Abasic DNA was hydrolyzed via 0.18 unit/!1L (2.0units enzyme total) over a
0-40 min time course (37°C incubation). At times indicated the reaction was quenched witb equal volumes 2.0 M
NaB~. Data standardized to the initial time point 0.0 min.
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The [mal incubation time for the APElRef-1 hydrolysis reaction is 2 mrn, which yielded
approximately 70% hydrolysis of the DNA substrate, approximately 88% of the total APElRef-1
hydrolysis, and the clearest measurable ratio of intact DNA substrate to hydrolyzed product.

Optimization ofelectrophoresis methodology eliminates single strand oligonucleotides from
reannealing.

Complications in quantifying the APElRef-l hydrolysis stenuned from an unknown and
unresolved band seen above Ihe intact DNA substrate maker. The molecular weight of the
unknown, the intact DNA substrate, and the hydrolyzed DNA product are unknown because a
32P-labeled DNA ladder was not available. The .uP-labeled DNA oligonucleotide was run on a
20% native mini gel via standard protocol to determine if there was an additional species present
in the labeled oligonucleotides prepared. Due to the high intensity of the radioactive label it
could not be determined conclusively whether the labeled oligonucleotide was one or two bands
(data not shown).

The labeled oligonucleotide was then run on a 15% denaturing

polyacrylamide mini gel against a Pol

~

DNA product to determine if the oligonucleotide was a

mixture of single and double stranded DNA, but the gel was too short to distinguish any
differences in banding patterns (data not shown). A larger, 20 em x 20

c~

15% denaturing gel

was rerun and illustrated the presence of only one band in the DNA substrate samples (Figure 7).
The denaturing gel ilhustrated that the oligomer is one intact strand and the unknown band does
not stem from the DNA substrate but arises during the UDG or APElRef- J assays. However, it
was important to note that the temperature of the mini gel was considerable higher than that in
the larger denaturing gels.
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1

2

3

Intact DNA
substrate
Pol

~

DNA product

Figure 7. Analysis of l2P-labeled DNA oligonucleotides on a J 5% denaruring PAGE. The gel was preheated at 500
V for 30 min and ran samples at 500 V for 50 min in lX TBE running buffer. Lane 1 represents a Pol ~ reaction
whereas lanes 2 and 3 were loaded with the labeled DNA substrate only.

Optimal denaturing polyacrylamide gels should be run between 45-50°C. A temperature
probe was adhered to one of the outside glass plates used in the vertical gel set up. The
temperature of the glass was recorded to measure the approximate temperature of the denaturing
gel over a 4.0 hr time course to reach a constant temperature of 45-50'C (results not shown).
The ftnal electrophoresis methodology included preheating the gel for 30 min at 475 V in an
empty/unloaded gel and running the gel for 30 min at 475 V to obtain a constant and
approximate 45-50·C gel temperature. It is important to note that the plates must be cooled upon
completion of electrophoresis for 15-30 min or the plates will crack. If the plates are run at a
temperature higher than 50'C, the plates will also crack.

The inhibition ofAPE/Ref-] hydrolysis activity by Cloretazine.

APElRef-l was pre-incubated with 40

~M

- 1.0 roM Cloretazine for 3.0 hr at room

temperature. Pre-incubation allowed approximately three half-lives of Cloretazine to occur so
that the effects of the enzyme were being examined on the enzyme and not the DNA substrate.
Cloretazine inhibited the activity of APElRef-l hydrolysis activity; however, the percent control
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activity vaJIues varied between replicates (figure 8). The assay volumes were increased by a
factor of tlU"ee to aCC01!l.Ot for possibte pipeting error.

1

2

3

4

S

6

7

8

9

10

Intact DNA substrate

Hydrolyzed DNA product

Figure 8. The ifIl:1ibition of APElRef-1 hydrolysis activity ,by 5 - 500, ~M Cloretazine. Samples were run on a 15%
denaturing PAGE, as described' in the methods. 'The conlJ'ols of the experiment included an intact 32 P-labeled DNA
substrate (lane t), a negative hydrolysis control 8 mM MgCh and no APEIRef-l, and two positive APE/Ref-I
hydrolysis saJn(llles without Cloretazine (lanes 3-4). The preincubations were run as follows; 500 ~M Cloretazine
and duplicate (Ian,es 5,8 respectively), 50 ~M Cloretazine and duplicate (lanes 6, 9, respectively), and 5 !-1M
Cloretazine and duplicate (lanes 7,10 respectively). Intact DNA and hydrolyzed DNA products are labeled.

APElRef-l was pre-incubated with 5 - 500 !lM Cloretazme for 3.0 hr at room
temperature. Cloretazme at 500 !J.M, 50 !J.M, and 5 !lM inhibited the activity of APElRef-1 with
percent control hydrolysis values of 81.8% ± 17, 125% ± 51, 148% ± 45, respectively.
Normalizing the hydrolysis to the positive and negative controls illustrates greater than 100%
hydrolysis of DN A, due to the decrease in activity of the positive control. Four positive rontrol
studies

Cn = 4 in duplicate) were prepared to determine the activity of the APEfRef-l.

The final

average hydrolysis of APElRef-l was 58.6% ± 15. The percent control hydrolysis values of the
effects of 500 J.1M, 50 !J.M, and 5 J.1M Cloreta1ine were normalized for the average control
hydrolysis and yielded: 53.7% ± 9, ,61.0% ± 9, 82.2% ± 26, respectively (Figure 9). The control
hydrolysls is 30% less active than the optimized activity of 70% detennined in the kinetics
experiment.

Consequently, a second kinetics study was performed to reassess the nature of
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APElRef-l activity that illustrated a fluxing, hyperbolic curve that reaches a maximum of 70%
hydrolysis after a 50 min incubation (Figure 10).
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Figure 9. Inhibition of APEJRef-ll hydrolysis activity by 5-500 I-lM Cloretazine concentrations for a 30 min UDG
reaction incubation followed by a 20 min APf.lRef-1 incubation. Total reaction v·olumes were quench~ with equal
volumes 2.0 M NaBr4, and run o.n 15% denaturing PAGE at 475 V for 30 mm. Samples were visl)alized via
phosphorimagry. Data were reponed as quadniplicate average.
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Figure 10. Second kinetics assessment of the hydrolysis of abasic DNA. Abasic DNA was hydrolyzed via 0.1&
unitl!JL total reaction volume (2.0units enzyme total') over a 0-50 min time course 37°C incubation. At times
indicated the reaction was quenched with equal volume 2.0 M NaBr4. Data were standardized to the initial time
point 0.1) min.
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DISCUSSION
Due to various chemical and physical DNA damaging agents, abasic sites are generated
within the genome.

The decrease in genomic stability can lead to complications in cell

development and cause apoptosis, cancer, or a variety of negative side effects. Various DNA
repair pathways are employed to maintain genomic stability. Understanding these mechanisms
can further enhance the treatments available in

OUI

chemotherapeutic arsenal.

The roles of

nitrosoureas as anticancer agents and their reactive subspecies, such as choroethylating and
carbamyolating species, have become increasing important in the future research to understand
the DNA repair mechanisms.

Studies have shown that Cloretazine directly inhibits AGT, a

predominant enzyme in direct DNA repair (16).

Methylisocyanate and the cWoroethylating

species inhibited AGT with ICso values of 13 !J.M and 100 j.LM, respectively (16). The effects of
Cloretazine in AGT versus AGT+ cell lines also increase the clinical utility of the drug. Cells
without AGT are more sensitive to Cloretazine compared to AGr cell lines treated with the
same concentration of alkyating agent (16). The research corresponds with clinical data, where
acute myelogenous leukemia patients with low AGT levels responded more favorably to
Cloretazine treatment than other treatments. Investigating alternative DNA repair mechanisms,
such as BER, can further reveal the utility of C1oretaz.ine over nitrosourea compounds.
In the absence of AGI, Pot
31). Cells deficient in Pol
inhibition of Pol

~

t3 may be used to repair alkylated DNA damage via BER (17,

are also more sensitive to DNA alkylating agents (31,32).

13 's AP lyase and

The

nucleoside transferase activity was investigated to begin the

investigation of BER. Cloretazine's carbamoylating activity inhibits the nucleotidyl transferase
activity of Pol-~, but not its lyase activity (A. Frederick and M. Davis, unpublished work). The
AP lyase activity was also inhibited by concentrations above clinically relevant levels. However,
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this study focused on developing an assay specific for APElRef-l hydrolysis and the effects of
Cloretazine on another BER enzyme. The enzyma1tic method that was developed focused on
determining ilie correct concentratio1!l of MgCh in the assay to aIIlow compfete APElRef-l
hydroly.sis, but to limit the amoumt of spontaneous deavage by the Mg 2+ cations. The optimal
concen.tration determined was 8.0 mM MgCb which does not show significant cleavage of DNA
but promotes APEfRef-1 hydrolysis.
Additional complications arose due to the electrophoretic method development, where
DNA oligonucleotides were reannealing within the 15% denaturing polyacrymide gel and
hindering the quantification of the analysis. The optimal gel temperature for complete denaturing
of the DNA substrates was between 45-50"C. Overall, the study provided preliminarily data
suggesting Cloretazine does not affect the APE/Ref-l hydrolysis activity at clinically significant
concentrations (Figure 9). 500 ~M, 50 IlM, and 5 ~M Cloretazine concentrations were tested on
APElRef-1 hydrolysis activity, and the results illustrate only 53.7% ± 9, 61.0% ± 9, 82.2% ± 26
percent control activity, respectively.

Over three orders of magnitude difference in drug

incubations, one would hope to see greater inhibition of APEfRef-1 activity in order to justify the
target.
The investigation of the APEfRef-l activity shows a decrease in percent control
hydrolysis dlllri..ng the time experiments (Figure 10). The assay was tested) to determine the
sow'ce of limiting enzymatic activity.

New APEfRef-l was pmcnased and the 32P-labeJ:ed

oligioEludeotrides were also investigated. These studies did not improve the overalll efficacy of
the assay. Consequently, the assay may be limited by the uraci.I-DNA glyocsylase activity. If
there is not enough enzymatic removal of the uracil in the labled oligonucleotide, then the
hydrolysis of the 5'-phosphodiester backbone cannot

OCCUF.

24

The study has only begun to investigate the importance of Cloretazine in other DNA
repair pathways. Inhibition of BER enzymes, in a predominant DNA repair pathway, such as
DNA Pol

~,

APElRef-l, FENl, and DNA Ligase III, couJd enhance Cloretazine's alkylating

agent by specifically targeting cells that overexpress DNA repair enzymes. The initial steps in
the investigation of how Cloretazine inhibits the hydrolysis activity of APElRef-l have achieved
promising resuJts. Further studies to fmalize the in vitro APElRef-l specific assay will allow the
complete assessment of bow Cloretazine, 90CE, lOlMDCE and BCNU affect APElRef-l
hydrolysis activity. The research would continue to determine other instances where Cloretazine
could be a more effective anticancer treatment compared to BCNU. Additional research will
illustrate the effects of the Cloretazine's chloroethylating and carbamoylating moieties compared
to the overall effects of BCND. The effects of APElRef-1 redox activity in vivo can promote
further research on APEJRef-l in the presence and absence of p53 transcription factors.
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